Drug Trial Radar · NCT00639678
A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Nov 15, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
322
Actual
Start
Mar 2008
Primary completion
Jul 2008
Study completion Sep 2008
Sponsor
- Lead sponsor
- Human Genome Sciences Inc.Industry
- Sponsor type
- Industry
- Collaborators
- GlaxoSmithKline; Emergent BioSolutions
- First posted
- Mar 20, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the safety and tolerability of raxibacumab in healthy subjects.
Conditions
- Healthy
Interventions
placeboDrug
40 mg/kg intravenously, double dose (day 0 and 14), Group 3
raxibacumabDrug
40 mg/kg intravenously, double dose (day 0 and 14), Group 1
placeboDrug
40 mg/kg placebo, single dose (day 0), Group 4
raxibacumabDrug
40 mg/kg intravenously, single dose, day 0, Group 2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment PeriodTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
- Number of Participants With Hematological Toxicities of the Indicated GradeTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
- Number of Participants With at Least a 2-grade Worsening From Baseline in Hematological ToxicitiesTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
- Number of Participants With Liver Toxicities of the Indicated GradeTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
- Number of Participants With at Least a 2-grade Worsening From Baseline in Liver ToxicitiesTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
- Number of Participants With Electrolyte Toxicities of the Indicated GradeTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
- Number of Participants With at Least a 2-grade Worsening From Baseline in Electrolyte ToxicitiesTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
- Number of Participants With Other Chemistry Toxicities of the Indicated GradeTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
- Number of Participants With at Least a 2-grade Worsening From Baseline in Other Chemistry ToxicitiesTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
- Number of Participants With Thyroid Toxicities of the Indicated GradeTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
- Number of Participants With Urinalysis Toxicities of the Indicated GradeTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
- Number of Participants With at Least a 2-grade Worsening From Baseline in Urinalysis ToxicitiesTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
- Number of Participants Who Developed an Anti-raxibacumab Antibody ResponseTime frame: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.